AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 247: H682-H685, 1984;
0363-6135/84 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olson, J. W.
Right arrow Articles by Gillespie, M. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olson, J. W.
Right arrow Articles by Gillespie, M. N.

AJP - Heart and Circulatory Physiology, Vol 247, Issue 4 682-H685, Copyright © 1984 by American Physiological Society

ARTICLES

Polyamines and the development of monocrotaline-induced pulmonary hypertension

J. W. Olson, A. D. Hacker, R. J. Altiere and M. N. Gillespie

Previous work in our laboratory has shown that the development of monocrotaline-induced pulmonary vascular disease in rats is preceded by a prolonged activation of lung ornithine decarboxylase (ODC). We now report that significant increases in rat lung adenosylmethionine decarboxylase activity and levels of the diamine putrescine and the polyamines, spermidine and spermine, are produced by a single dose of monocrotaline (MCT). Lung putrescine levels were increased from days 7 through 21, and both spermidine and spermine were first elevated at day 10 following MCT administration. This sustained elevation of lung polyamine levels substantially preceded the development of right ventricular hypertrophy and pulmonary hypertension, which were first evident at days 14 and 16, respectively. Continuous treatment with alpha-difluoromethylornithine, a highly specific enzyme-activated, irreversible inhibitor of ODC activity, prevented the development of MCT-induced pulmonary toxicity. It thus appears that ODC and the polyamines may be important mediators of hypertensive pulmonary vascular disease that develops in response to monocrotaline administration.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. Ruchko, M. N. Gillespie, R. S. Weeks, J. W. Olson, and P. Babal
Putrescine transport in hypoxic rat main PASMCs is required for p38 MAP kinase activation
Am J Physiol Lung Cell Mol Physiol, January 1, 2003; 284(1): L179 - L186.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Babál, M. Ruchko, C. C. Campbell, S. P. Gilmour, J. L. Mitchell, J. W. Olson, and M. N. Gillespie
Regulation of Ornithine Decarboxylase Activity and Polyamine Transport by Agmatine in Rat Pulmonary Artery Endothelial Cells
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 372 - 377.
[Abstract] [Full Text]

Home page
 J. Appl. Physiol.Home page
G. L. Colice, N. Hill, Y.-J. Lee, H. Du, J. Klinger, J. C. Leiter, and L.-C. Ou
Exaggerated pulmonary hypertension with monocrotaline in rats susceptible to chronic mountain sickness
J Appl Physiol, July 1, 1997; 83(1): 25 - 31.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online